Devin Smith Net Worth

Devin Smith biography

Devin Whittemore Smith serves as Senior Vice President, General Counsel of the Company. Mr. Smith has provided services to us since July 2018. Mr. Smith has more than 19 years of legal and compliance experience serving clients in the biotechnology and pharmaceutical industries. Prior to joining us, Mr. Smith served as served as General Counsel and Company Secretary of Stallergenes Greer plc, a global biopharmaceutical company focused on allergy immunotherapy products, beginning in October 2015. From October 2011 until October 2015, Mr. Smith was the Vice President and General Counsel and led the North American legal department for EMD Serono, Inc., the biopharmaceutical division of Merck KGaA. From October 2006 until October 2011, he was the Associate General Counsel for EMD Serono. Prior to EMD Serono, he was a partner at the international law firm of Nixon Peabody LLP. Mr. Smith currently serves on the board of directors of Chainfast Incorporated. Mr. Smith received a B.A. from the University of North Carolina- Chapel Hill and his law degree (cum laude) from Suffolk University Law School.

What is the salary of Devin Smith?

As the Senior Vice President und General Counsel of Minerva Neurosciences Inc, the total compensation of Devin Smith at Minerva Neurosciences Inc is $2,044,250. There are 1 executives at Minerva Neurosciences Inc getting paid more, with Michael Davidson having the highest compensation of $2,842,430.

How old is Devin Smith?

Devin Smith is 52, he's been the Senior Vice President und General Counsel of Minerva Neurosciences Inc since 2018. There are 18 older and 2 younger executives at Minerva Neurosciences Inc. The oldest executive at Minerva Neurosciences Inc is David Kupfer, 79, who is the Independent Director.

What's Devin Smith's mailing address?

Devin's mailing address filed with the SEC is 1601 Trapelo Rd #286, Waltham, MA 02451, USA.

Insiders trading at Minerva Neurosciences Inc

Over the last 10 years, insiders at Minerva Neurosciences Inc have traded over $49,043,620 worth of Minerva Neurosciences Inc stock and bought 8,182,692 units worth $47,876,311 . The most active insiders traders include & Johnson Johnson & Johnson..., Venture Associates Iii Ltd ... und Capital Iii Llc Care Capita.... On average, Minerva Neurosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of $556,476. The most recent stock trade was executed by Remy Luthringer on 28 April 2023, trading 27,394 units of NERV stock currently worth $105,193.

What does Minerva Neurosciences Inc do?

minerva neurosciences, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. its lead product candidate is roluperidone, which is in phase iii clinical trial, a compound for the treatment of schizophrenia. the company is also developing seltorexant that has completed phase iib clinical trial for treating insomnia and major depressive disorders; and min-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of parkinson's disease. minerva neurosciences, inc. has a license agreement with mitsubishi tanabe pharma corporation for the development and commercialization of the roluperidone worldwide, excluding asia; and co-development and license agreement with janssen pharmaceutica, n.v. for the development of seltorexant. the company was formerly known as cyrenaic pharmaceuticals, inc. and changed its

Minerva Neurosciences Inc executives and stock owners

Minerva Neurosciences Inc executives and other stock owners filed with the SEC include:

• Michael Davidson,
  Chief Medical Officer
• Devin Smith,
  Senior Vice President, General Counsel
• Remy Luthringer,
  Chief Executive Officer and Executive Chairman of the Board of Directors
• Geoffrey Race,
  Executive Vice President, Chief Financial Officer and Chief Business Officer
• Dr. Remy Luthringer Ph.D.,
  Exec. Chairman & CEO
• Frederick Ahlholm,
  Senior Vice President, Chief Accounting Officer
• Dr. Rémy Luthringer,
  Exec. Chairman & CEO
• Geoffrey Robin Race F.C.M.A., FCMA, M.B.A., MBA,
  Pres
• Dr. Jay B. Saoud Ph.D.,
  Consultant
• William Doyle,
  Lead Independent Director
• Jan van Heek,
  Independent Director
• Jeryl Hilleman,
  Independent Director
• Hans Hasler,
  Independent Director
• David Kupfer,
  Independent Director
• Fouzia Laghrissi-Thode,
  Independent Director
• William Boni,
  IR Contact Officer
• Jay Saoud,
  Senior Vice President, Head of Research and Development
• Joseph Reilly,
  Chief Operating Officer, Senior Vice President
• Dr. Ramana Kuchibhatla Ph.D.,
  Sr. VP and Head of R&D
• Dr. Michael Davidson M.D.,
  Chief Medical Officer
• Joseph Reilly,
  Sr. VP & COO
• Frederick W. Ahlholm CPA, CPA,
  Chief Financial Officer
• William B. Boni,
  VP of Investor Relations & Corp. Communications
• Marc D Beer,
  Director
• Mark S. Levine,
  SVP,General Counsel & Sec.
• Michele Ollier,
  Director
• Venture Associates Iii Ltd ...,
  
• Nico Vandervelpen,
  Director
• Rubertis Francesco De,
  Director
• Richard E. Russell,
  President
• & Johnson Johnson & Johnson...,
  
• Capital Iii Llc Care Capita...,
  
• Coelho Rogerio Vivaldi,
  President and CEO
• Lorenzo Pellegrini,
  Director
• Geoff Race,
  President
• Plc Barclays,
  10% owner